Summary
Researchers want to know if sacituzumab tirumotecan given alone or with pembrolizumab can treat triple negative breast cancer (TNBC). The main goal of this study is to learn if people treated with sacituzumab tirumotecan alone or with pembrolizumab live longer overall or without the cancer growing or spreading compared to people treated with chemotherapy.
Official Title
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)
Keywords
Triple Negative Breast Neoplasms, Programmed Cell Death-1 (PD1, PD-1), Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1), Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2), Antibody-drug conjugate (ADC), Trophoblast cell-surface antigen 2 (TROP2), Autosomal Dominant Lewy Body Parkinson Disease 4, pembrolizumab, Paclitaxel, 130-nm albumin-bound paclitaxel, Albumin-Bound Paclitaxel, Gemcitabine, Carboplatin, Sacituzumab tirumotecan, Rescue Medication, Nab-paclitaxel, Sacituzumab Tirumotecan + Pembrolizumab